GlassScriptPhysician profile
Calvin M Snipes
NPI 1225023484
$4,463.00
in general payments reported to CMS, 2019-2025
36 companies · $51.60 in 2025
The $51.60 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $672 · 2021: $629 · 2022: $1,149 · 2023: $701 · 2025: $51.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $795.88 | 2019-2023 | Ozempic, Tresiba, Rybelsus |
| Janssen Pharmaceuticals, INC | $474.66 | 2019-2022 | |
| Lilly USA, LLC | $393.88 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $386.56 | 2019-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $351.67 | 2019-2023 | |
| Abbvie INC. | $246.50 | 2019-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $239.74 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $187.61 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $165.13 | 2019-2023 | Farxiga |
| Dexcom, INC. | $123.08 | 2021-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $122.25 | 2021-2023 | |
| Abbott Laboratories | $114.13 | 2021-2023 | Freestyle Libre 3, Octrode |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.00 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $79.68 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $78.64 | 2020-2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Snipes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.